Physician profile
Mark David Braden
NPI 1912490905
$7,925.87
in general payments reported to CMS, 2019-2025
31 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 91% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.02 · 2021: $274 · 2022: $1,219 · 2023: $2,763 · 2024: $1,990 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,155 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,154.92 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,289.31 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,149.65 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,116.20 | 2021-2025 | Tavneos, Evenity, Avsola |
| Ani Pharmaceuticals, INC. | $557.97 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $429.93 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $411.28 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $273.67 | 2021-2025 | Taltz, Zepbound |
| Organon LLC | $224.68 | 2023-2024 | Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.35 | 2021-2024 | Ofev, Cyltezo |
| Janssen Scientific Affairs, LLC | $183.74 | 2022-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $123.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $107.98 | 2019-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $96.56 | 2022-2024 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Radius Health, INC. | $95.60 | 2023-2025 | Tymlos |
| Sandoz INC. | $83.86 | 2023-2025 | Hyrimoz, Jubbonti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $71.18 | 2023-2025 | |
| Abbvie INC. | $60.95 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $60.67 | 2022-2023 | Lupkynis |
| Kyowa Kirin, INC. | $58.47 | 2023-2025 | Crysvita |
| Alvogen INC | $54.01 | 2023-2025 | Teriparatide |
| Pfizer INC. | $51.36 | 2021 | |
| Genzyme Corporation | $36.87 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $32.79 | 2025 | |
| Bioventus LLC | $28.92 | 2022-2025 | Durolane |
| Actelion Pharmaceuticals US, INC. | $26.74 | 2022 | |
| United Therapeutics Corporation | $25.44 | 2023 | Tyvaso |
| Mallinckrodt Enterprises LLC | $19.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.16 | 2023 | Hyqvia |
| Genentech USA, INC. | $17.95 | 2024 | Actemra |
| Biocon Biologics INC | $13.61 | 2024 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Braden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.